Literature DB >> 11790164

Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples.

Osvaldo Correia1, Luis Delgado, Jean-Claude Roujeau, Laurence Le Cleach, José A Fleming-Torrinha.   

Abstract

BACKGROUND: Toxic epidermal necrolysis (TEN) is a rare but severe adverse drug disease, characterized by extensive skin and mucosal detachment with participation of different immunoinflammatory pathways, in particular with early participation of activated CD8+ T lymphocytes.
OBJECTIVE: To further study the potential role of T lymphocytes in the early phase of keratinocyte necrosis.
DESIGN: Prospective study.
SETTING: University hospitals. PATIENTS: Thirteen patients with clinical and histopathologic criteria of TEN and 6 patients with second-degree burns. MAIN OUTCOME MEASURES: Measurement of soluble interleukin (IL) 2 receptor (sIL-2R) and IL-1alpha in serum samples and fluid of recent blisters.
RESULTS: In the blister fluid of patients with TEN, we found significantly higher levels of sIL-2R than in patients with burns, whereas IL-1alpha levels were higher in the blister fluid of burned patients. No significant differences were found in serum samples of patients with TEN and burns, in either sIL-2R or IL-1alpha. In TEN we also found significantly higher levels of sIL-2R in the blister fluid compared with serum samples, pointing to a predominantly local production contrasting with the low concentration of sIL-2R in the blister fluid of burned patients.
CONCLUSIONS: Our findings of elevated sIL-2R levels in blister fluid of patients with TEN are probably related to a local down-regulation of an immunologically mediated cytotoxic reaction and further support the involvement of activated T lymphocytes in the early blisters of TEN.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11790164     DOI: 10.1001/archderm.138.1.29

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  8 in total

1.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

2.  Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome.

Authors:  Mayumi Ueta; Chie Sotozono; Tsutomu Inatomi; Kentaro Kojima; Kei Tashiro; Junji Hamuro; Shigeru Kinoshita
Journal:  Br J Ophthalmol       Date:  2007-02-21       Impact factor: 4.638

3.  Topical ophthalmic cyclosporine in the treatment of toxic epidermal necrolysis.

Authors:  Zafer Onaran; Gülşah Usta; Mukadder Koçak; Kemal Ornek; Unase Büyükkoçak
Journal:  Case Rep Med       Date:  2011-12-27

Review 4.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

5.  Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1.

Authors:  Claudia Heijmans-Antonissen; Feikje Wesseldijk; Renate Jm Munnikes; Frank Jpm Huygen; Patrick van der Meijden; Wim C J Hop; Herbert Hooijkaas; Freek J Zijlstra
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

Review 6.  Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Akito Hasegawa; Riichiro Abe
Journal:  F1000Res       Date:  2020-06-16

7.  Drug induced toxic epidermal necrolysis: two case reports.

Authors:  Syed Nurul Rasool Qadir; Naeem Raza; Fozi Qadir
Journal:  Cases J       Date:  2009-09-09

8.  HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese.

Authors:  Mayumi Ueta; Katsushi Tokunaga; Chie Sotozono; Tsutomu Inatomi; Toshio Yabe; Masaki Matsushita; Yoko Mitsuishi; Shigeru Kinoshita
Journal:  Mol Vis       Date:  2008-03-17       Impact factor: 2.367

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.